Recent Advances in Management of Sarcoidosis-Associated Fatigue: A Narrative Review
Keywords:
pulmonary sarcoidosis, sarcoidosis associated fatigue, exercise training, pulmonary rehabilitation, Treatment of sarcoidosisAbstract
Background and aim: Sarcoidosis-associated fatigue (SAF) occurs in approximately 30% to 90% of patients. While previous reviews examined select medications, these omitted nonpharmacological and emerging treatments that could significantly improve fatigue for individuals with sarcoidosis. Limited guidance exists for excluding alternative causes of fatigue and selecting between treatment options for these patients. This narrative review synthesized pharmacological and nonpharmacological interventions for SAF and interpreted evidence strength to guide clinical decision-making.
Methods: PubMed was queried in December 2025 for clinical trials, reviews, and meta-analyses published within the last 10 years. This yielded 41 results which were supplemented by manual review of bibliographies, clinical guidelines, and a search of the Cochrane Library. Evidence was interpreted and analyzed for quality using a modified GRADE-informed approach.
Results: Treatment of active disease with prednisone or methotrexate improves systemic inflammation but may paradoxically worsen fatigue with chronic use. Stimulants (e.g., dexmethylphenidate, armodafinil) display low-quality evidence for improving SAF and side effects may be prohibitive for some patients. TNF-α inhibitors (e.g., infliximab) have very low-quality evidence with few studies and negative findings. Pulmonary rehabilitation and exercise training show low-to-moderate quality evidence with few adverse effects but lack specific implementation protocols.
Conclusions: Diagnosis of SAF requires exclusion of alternative causes which may be challenging. Active disease should be treated appropriately while monitoring for adverse effects. Despite low-to-moderate quality evidence for most interventions, nonpharmacological approaches (e.g., pulmonary rehabilitation, exercise) are recommended as first-line therapy given favorable risk-benefit profiles. Larger, well-designed RCTs are needed given the substantial disease burden.
References
1. Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primer. 2019 Jul 4;5(1):45. doi:10.1038/s41572-019-0096-x
2. Partin M, Clebak KT, Chen R, Helm M. Sarcoidosis: Evaluation and Treatment. Am Fam Physician. 2024 Jan;109(1):19–29.
3. Tavee J, Culver D. Nonorgan manifestations of sarcoidosis. Curr Opin Pulm Med. 2019 Sep 1;25(5):533–8. doi:10.1097/MCP.0000000000000597
4. Voortman M, Hendriks CMR, Elfferich MDP, Bonella F, Møller J, De Vries J, et al. The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung. 2019 Apr 15;197(2):155–61. doi:10.1007/s00408-019-00206-7
5. Górski W, Piotrowski WJ. Fatigue syndrome in sarcoidosis. Pneumonol Alergol Pol. 2016;84(4):244–50. doi:10.5603/PiAP.2016.0030
6. Bloem AEM, Mostard RLM, Stoot N, Vercoulen JH, Peters JB, Spruit MA. Perceptions of fatigue in patients with idiopathic pulmonary fibrosis or sarcoidosis. J Thorac Dis. 2021 Aug;13(8):4872–84. doi:10.21037/jtd-21-462
7. de Kleijn WP, Drent M, Vermunt JK, Shigemitsu H, De Vries J. Types of fatigue in sarcoidosis patients. J Psychosom Res. 2011 Dec;71(6):416–22. doi:10.1016/j.jpsychores.2011.09.006
8. Drent M, Wirnsberger RM, De Vries J, Van Dieijen-Visser MP, Wouters EFM, Schols AMWJ. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J. 1999 Apr;13(4):718–22. doi:10.1034/J.1399-3003.1999.13D03.X
9. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012 Jul;40(1):255–63. doi:10.1183/09031936.00002512
10. Liu A, Sharma L, Yan X, Dela Cruz CS, Herzog EL, Ryu C. Emerging insights in sarcoidosis: moving forward through reverse translational research. Am J Physiol Lung Cell Mol Physiol. 2022 Apr 1;322(4):L518–25. doi:10.1152/AJPLUNG.00266.2021
11. Judson MA. The Clinical Features of Sarcoidosis: A Comprehensive Review. Clin Rev Allergy Immunol. 2015 Aug;49(1):63–78. doi:10.1007/s12016-014-8450-y
12. Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of Sarcoidosis. Clin Chest Med. 2015 Dec;36(4):727–37. doi:10.1016/j.ccm.2015.08.013
13. Fiorini V, Hu B, Sun Y, Yu S, McGovern J, Gandhi S, et al. Circulating Mitochondrial DNA Is Associated With High Levels of Fatigue in Two Independent Sarcoidosis Cohorts. Chest. 2024 May;165(5):1174–85. doi:10.1016/j.chest.2023.11.020
14. Wessendorf TE, Bonella F, Costabel U. Diagnosis of Sarcoidosis. Clin Rev Allergy Immunol. 2015 Aug;49(1):54–62. doi:10.1007/s12016-015-8475-x
15. Lal C, Medarov BI, Judson MA. Interrelationship between sleep-disordered breathing and sarcoidosis. Chest. 2015 Oct;148(4):1105–14. doi:10.1378/chest.15-0584
16. Fleischer M, Hinz A, Brähler E, Wirtz H, Bosse-Henck A. Factors associated with fatigue in sarcoidosis. Respir Care. 2014 Jul;59(7):1086–94. doi:10.4187/RESPCARE.02080
17. Hendriks C, Drent M, de Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study. Respir Med. 2018 May;138S:S24–30. doi:10.1016/j.rmed.2017.11.008
18. Benn BS, Lehman Z, Kidd SA, Miaskowski C, Sunwoo BY, Ho M, et al. Sleep disturbance and symptom burden in sarcoidosis. Respir Med. 2018 Nov;144S:S35–40. doi:10.1016/j.rmed.2018.03.021
19. Atkins C, Wilson AM. Managing fatigue in sarcoidosis - A systematic review of the evidence. Chron Respir Dis. 2017 May;14(2):161–73. doi:10.1177/1479972316661926
20. Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021 Dec 16;58(6):2004079. doi:10.1183/13993003.04079-2020
21. Vis R, van de Garde EMW, Grutters JC, Korenromp IHE. The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: A systematic review. Eur Respir Rev. 2020 Jan 29;29(155):190057. doi:10.1183/16000617.0057-2019
22. Wells AU, Lower EE, Baughman RP, Culver DA, Judson MA, Bonham CA, et al. A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders. Lancet Respir Med. 2025 Nov 6. doi:10.1016/S2213-2600(25)00338-8
23. Grongstad A, Vøllestad NK, Oldervoll LM, Spruit MA, Edvardsen A. The acute impact of resistance training on fatigue in patients with pulmonary sarcoidosis. Chron Respir Dis. 2020 Jan;17:1479973120967024. doi:10.1177/1479973120967024
24. Crouser ED, Maier LA, Baughman RP, Abston E, Bernstein RC, Blankstein R, et al. Diagnosis and Detection of Sarcoidosis An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Apr 15;201(8):E26–51. doi:10.1164/RCCM.202002-0251ST
25. Tana C, Drent M, Obi ON, Cinetto F, Bernardinello N, Moffa L, et al. Multidisciplinary strategies and new technologies in the management of sarcoidosis. Eur J Intern Med. 2026 Feb;144:106576. doi:10.1016/j.ejim.2025.106576
26. Bechman K, Russell MD, Biddle K, Gibson M, Adas M, Yang Z, et al. Incidence, prevalence, and mortality of sarcoidosis in England: a population-based study. Lancet Reg Health Eur. 2025 Apr 4;53:101283. doi:10.1016/j.lanepe.2025.101283
27. De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004 Sep;9(3):279–91. doi:10.1348/1359107041557048
28. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011 Apr;64(4):401–6. doi:10.1016/j.jclinepi.2010.07.015
29. Atkins C, Jones A, Clark AB, Stockl A, Fordham R, Wilson AM. Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): A double-blind, parallel-arm randomised feasibility trial. BMJ Open Respir Res. 2021 May;8(1):e000814. doi:10.1136/bmjresp-2020-000814
30. Logan N, Raja J, Renzoni EA. Treating sarcoidosis: when less is more. Curr Opin Immunol. 2025 Dec;97:102679. doi:10.1016/j.coi.2025.102679
31. U.S. Food and Drug Administration. Cephalon, LLC NUVIGIL- armodafinil tablet HUMAN PRESCRIPTION DRUG LABEL [Internet]. 2022 [cited 2025 Nov 23]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d878aed0-ddbf-8fa1-abf7-d3e480260845
32. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008 May;133(5):1189–95. doi:10.1378/chest.07-2952
33. Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: A double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage. 2013 Feb;45(2):159–69. doi:10.1016/j.jpainsymman.2012.02.016
34. U.S. Food and Drug Administration. Teva Pharmaceuticals USA, Inc. DEXMETHYLPHENIDATE HYDROCHLORIDE- dexmethylphenidate hydrochloride capsule, extended release HUMAN PRESCRIPTION DRUG LABEL [Internet]. 2025 [cited 2026 Jan 14]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd659d39-41f5-4612-8f17-bad602b4784d
35. Frye BC, Potasso L, Farin-Glattacker E, Birring S, Müller-Quernheim J, Schupp JC. FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients. BMC Pulm Med. 2021 Dec 3;21(1):395. doi:10.1186/s12890-021-01761-7
36. Black JE, Hull SG, Tiller J, Yang R, Harsh JR. The Long-Term Tolerability and Efficacy of Armodafinil in Patients with Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder, or Narcolepsy: An Open-Label Extension Study. J Clin Sleep Med. 2010 Oct 15;6(5):458–66.
37. de Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med. 2011 Sep;105(9):1388–95. doi:10.1016/j.rmed.2011.05.004
38. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711–23. doi:10.1056/NEJMra050541
39. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J. 2006 Sep;28(3):627–36. doi:10.1183/09031936.06.00105805
40. Zhang Y, Jiang X, Wang Q, Wu J, Zhou J. Dexamethasone alleviates pulmonary sarcoidosis by regulating the TGF-β/Smad3 signaling to promote Th17/Treg cell rebalance. Cell Immunol. 2024 Jan;395–396:104781. doi:10.1016/j.cellimm.2023.104781
41. Broos CE, Wapenaar M, Looman CWN, in’t Veen JCCM, van den Toorn LM, Overbeek MJ, et al. Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. Eur Respir J. 2018 Jan;51:1702089. doi:10.1183/13993003.02089-2017
42. Aggarwal AN, Sahu KK, Gupta D. Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis. 2016 Aug 1;33(2):124–9.
43. Vis R, van de Garde EMW, Meek B, Korenromp IHE, Grutters JC. Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis. Respir Med. 2020 Apr;165:105936. doi:10.1016/j.rmed.2020.105936
44. Baughman RP, Sweiss N, Keijsers R, Birring SS, Shipley R, Saketkoo LA, et al. Repository corticotropin for Chronic Pulmonary Sarcoidosis. Lung. 2017 Jun;195(3):313–22. doi:10.1007/s00408-017-9994-4
45. Fardet L, Petersen I, Nazareth I. Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. Medicine (Baltimore). 2015 Apr;94(15):e647. doi:10.1097/MD.0000000000000647
46. Miyake K, Kawamura T, Nakahara Y, Sasaki S. A single-center, person-month-based analysis of the risk of developing Pneumocystis pneumonia (PCP) in immunosuppressed non-HIV patients: Preventive effects of trimethoprim-sulfamethoxazole. J Infect Chemother. 2023 Dec;29(12):1097–102. doi:10.1016/j.jiac.2023.07.012
47. Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Dogra P, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). Eur Respir J. 2023 Sep 9;62(3):2300198. doi:10.1183/13993003.00198-2023
48. Rebelo P, Oliveira A, Andrade L, Valente C, Marques A. Minimal Clinically Important Differences for Patient-Reported Outcome Measures of Fatigue in Patients With COPD Following Pulmonary Rehabilitation. Chest. 2020 Aug;158(2):550–61. doi:10.1016/j.chest.2020.02.045
49. Nunes H, Jeny F, Bouvry D, Uzunhan Y, Valeyre D. Indications for treatment of sarcoidosis. Curr Opin Pulm Med. 2019 Sep;25(5):505–18. doi:10.1097/MCP.0000000000000604
50. Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN. Trends and Characteristics of US Medicare Spending on Repository Corticotropin. JAMA Intern Med. 2017 Nov 1;177(11):1680–2. doi:10.1001/jamainternmed.2017.3631
51. Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: A prospective observational study using FDG-PET. Clin Respir J. 2012 Oct;6(4):238–47. doi:10.1111/j.1752-699X.2011.00276.x
52. Adler BL, Wang CJ, Bui TL, Schilperoort HM, Armstrong AW. Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. Semin Arthritis Rheum. 2019 Jun;48(6):1093–104. doi:10.1016/j.semarthrit.2018.10.005
53. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration. 2010;80(3):212–9. doi:10.1159/000314225
54. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013 May;68(5):765–73. doi:10.1016/j.jaad.2012.10.056
55. Van Rijswijk HN, Vorselaars AD, Ruven HJ, Keijsers RG, Zanen P, Korenromp IH, et al. Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment. Expert Opin Orphan Drugs. 2013;1(6):437–43. doi:10.1517/21678707.2013.797891
56. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):713–20. doi:10.1007/S00417-011-1844-0
57. Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Nov;142(5):e1S-e111S. doi:10.1378/chest.12-1044
58. Paglinco SR, Abdel-Rasoul M, McNicol M, Mouslim MC, Boyle B, Dotson JL, et al. The biosimilar shift: trending infliximab biosimilar utilization and associated cost savings for commercial insurance. Am J Manag Care. 2025 Oct 1;31(10):e295–301. doi:10.37765/AJMC.2025.89811
59. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial. Eur Respir J. 2008 Jun;31(6):1189–96. doi:10.1183/09031936.00051907
60. Bechman K, Biddle K, Miracle A, He K, Gibson M, Russell MD, et al. Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis. Thorax. 2025 Sep 15;80(10):702–10. doi:10.1136/thorax-2025-223014
61. Alqarni AM, Zeidler MP. How does methotrexate work? Biochem Soc Trans. 2020 Apr 29;48(2):559–67. doi:10.1042/BST20190803
62. Kahlmann V, Janssen Bonás M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk HNAJ, et al. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. N Engl J Med. 2025 Jul 17;393(3):231–42. doi:10.1056/nejmoa2501443
63. Van Ede AE, Laan RF, Blom HJ, De Abreu RA, Van de Putte LB. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998 Apr;27(5):277–92. doi:10.1016/S0049-0172(98)80049-8
64. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001 Nov;15(11):1699–708. doi:10.1046/j.1365-2036.2001.01102.x
65. Stevenson M, Nakafero G, Williams HC, Card T, Taal MW, Aithal GP, et al. Cost-effectiveness of risk-stratified blood-test monitoring strategies for adults with inflammatory conditions. Rheumatol Oxf. 2025 Nov 21;keaf623. doi:10.1093/RHEUMATOLOGY/KEAF623
66. Obi ON. Anti-inflammatory Therapy for Sarcoidosis. Clin Chest Med. 2024 Mar;45(1):131–57. doi:10.1016/j.ccm.2023.08.010
67. Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, et al. Efzofitimod for the Treatment of Pulmonary Sarcoidosis. Chest. 2023 Apr;163(4):881–90. doi:10.1016/j.chest.2022.10.037
68. aTyr Pharma, Inc. ClinicalTrials.gov identifier: NCT05415137 [Internet]. Bethesda, MD: National Library of Medicine; 2022 [cited 2025 Nov 26]. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis. Available from: https://clinicaltrials.gov/study/NCT05415137
69. aTyr Pharma, Inc. aTyr Pharma Announces Topline Results from Phase 3 EFZO-FITTM Study of Efzofitimod in Pulmonary Sarcoidosis [Internet]. 2025 [cited 2025 Dec 15]. Available from: https://investors.atyrpharma.com/node/16626/pdf
70. Vermeer B, Veltkamp M, Raasing LRM, Wind AE, Vorselaars ADM. Hydroxychloroquine monotherapy in sarcoidosis: Indications, efficacy, and side effects. Sarcoidosis Vasc Diffuse Lung Dis. 2024 Sep 24;41(3):e2024039. doi:10.36141/svdld.v41i3.15445
71. de Kleijn WP, Elfferich MD, De Vries J, Jonker GJ, Lower EE, Baughman RP, et al. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):92–7.
72. ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation. Obstet Gynecol. 2019 Apr;133(4):e287–95. doi:10.1097/AOG.0000000000003176
73. Crouser ED, Smith RM, Culver DA, Julian MW, Martin K, Baran J, et al. A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis. Chest. 2021 Oct;160(4):1340–9. doi:10.1016/j.chest.2021.05.031
74. Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021 Feb 1;2(2). doi:10.1002/14651858.CD006322.PUB4
75. Alsina-Restoy X, Torres-Castro R, Caballería E, Gimeno-Santos E, Solis-Navarro L, Francesqui J, et al. Pulmonary rehabilitation in sarcoidosis: A systematic review and meta-analysis. Respir Med. 2023 Nov;219:107432. doi:10.1016/j.rmed.2023.107432
76. Grongstad A, Spruit MA, Oldervoll LM, Vøllestad NK, Edvardsen A. Pulmonary Rehabilitation in Patients with Pulmonary Sarcoidosis: Impact on Exercise Capacity and Fatigue. Respiration. 2020;99(4):289–97. doi:10.1159/000506295
77. Blackwell JEM, Doleman B, Herrod PJJ, Ricketts S, Phillips BE, Lund JN, et al. Short-Term (<8 wk) High-Intensity Interval Training in Diseased Cohorts. Med Sci Sports Exerc. 2018 Sep;50(9):1740–9. doi:10.1249/MSS.0000000000001634
78. Wallaert B, Kyheng M, Labreuche J, Stelianides S, Wemeau L, Grosbois JM. Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial. Respir Med Res. 2020 Mar;77:1–7. doi:10.1016/j.resmer.2019.10.003
79. Strookappe B, Saketkoo LA, Elfferich M, Holland A, De Vries J, Knevel T, et al. Physical activity and training in sarcoidosis: review and experience-based recommendations. Expert Rev Respir Med. 2016 Oct;10(10):1057–68. doi:10.1080/17476348.2016.1227244
80. Guber E, Wand O, Epstein Shochet G, Romem A, Shitrit D. The Short- And Long-Term Impact of Pulmonary Rehabilitation in Subjects with Sarcoidosis: A Prospective Study and Review of the Literature. Respiration. 2021;100(5):423–31. doi:10.1159/000514917
81. Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients with Stage 3 and 4 Sarcoidosis A RANDOMIZED CONTROLLED TRIAL. J Cardiopulm Rehabil Prev. 2018 Mar;38(2):124–30. doi:10.1097/HCR.0000000000000307
82. Tahmaz T, Aslan GK, Yeldan İ, Okumuş NG. Comparison of the effects of one-legged and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. Respir Med. 2025 Nov;248:108380. doi:10.1016/j.rmed.2025.108380
83. Karadallı MN, Boşnak-Güçlü M, Camcıoğlu B, Kokturk N, Tüktaş H. Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial. Respir Care. 2016 Apr;61(4):483–94. doi:10.4187/respcare.04312
84. Marcellis R, Van der Veeke M, Mesters I, Drent M, De Bie R, De Vries G, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22;32(1):53–62.
85. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10):1428–9. doi:10.1016/j.jacc.2019.03.009
86. Pober DM, Braun B, Freedson PS. Effects of a single bout of exercise on resting heart rate variability. Med Sci Sports Exerc. 2004 Jul;36(7):1140–8. doi:10.1249/01.MSS.0000132273.30827.9A
87. Laforgia J, Withers RT, Gore CJ. Effects of exercise intensity and duration on the excess post-exercise oxygen consumption. J Sports Sci. 2006 Dec;24(12):1247–64. doi:10.1080/02640410600552064
88. Franssen WMA, Franssen GHLM, Spaas J, Solmi F, Eijnde BO. Can consumer wearable activity tracker-based interventions improve physical activity and cardiometabolic health in patients with chronic diseases? A systematic review and meta-analysis of randomised controlled trials. Int J Behav Nutr Phys Act. 2020 May 11;17(1):57. doi:10.1186/S12966-020-00955-2
89. Drent M, Elfferich M, Breedveld E, De Vries J, Strookappe B. Benefit of Wearing an Activity Tracker in Sarcoidosis. J Pers Med. 2020 Aug 22;10(3):97. doi:10.3390/JPM10030097
90. James WE, Chandler J, Benfield K, Pairet S, Hoffman M, Mueller M, et al. A mHealth app for sarcoidosis-associated fatigue: a feasibility randomized control trial. Respir Med. 2025 Dec;250:108490. doi:10.1016/j.rmed.2025.108490
91. Kahlmann V, Moor CC, Van Helmondt SJ, Mostard RLM, Van Der Lee ML, Grutters JC, et al. Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial. Lancet Respir Med. 2023 Mar;11(3):265–72. doi:10.1016/S2213-2600(22)00387-3
92. Chandler J, Christon LM, Benfield K, Pairet S, Hoffman M, Treiber F, et al. Design and rationale of a pilot randomized clinical trial investigating the use of a mHealth app for sarcoidosis-associated fatigue. Contemp Clin Trials Commun. 2023 Jan 16;32:101062. doi:10.1016/J.CONCTC.2023.101062
93. Latimer KM, Gunther A, Kopec M. Fatigue in Adults: Evaluation and Management. Am Fam Physician. 2023 Jul;108(1):58–69.
94. Brito-Zerón P, Acar-Denizli N, Sisó-Almirall A, Bosch X, Hernández F, Vilanova S, et al. The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases. Lung. 2018 Apr;196(2):239–48. doi:10.1007/s00408-017-0076-4
95. Judson MA. The treatment of sarcoidosis: Translating the European respiratory guidelines into clinical practice. Curr Opin Pulm Med. 2022 Sep 1;28(5):451–60. doi:10.1097/MCP.0000000000000896
96. Hendriks C, Drent M, Elfferich M, De Vries J. The Fatigue Assessment Scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med. 2018 Sep;24(5):495–503. doi:10.1097/MCP.0000000000000496
97. Mokros Ł, Miłkowska-Dymanowska J, Gwadera Ł, Pietras T, Piotrowski W. Chronotype and the Big-Five personality traits as predictors of chronic fatigue among patients with sarcoidosis. A cross-sectional study. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Jun 29;40(2):e2023018. doi:10.36141/SVDLD.V40I2.12889
98. Nii T, Kuzuya K, Kabata D, Matsui T, Murata A, Ohya T, et al. Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor –kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking. J Autoimmun. 2019 Mar;98:95–102. doi:10.1016/j.jaut.2018.12.004
99. Li H, Zhao J, Liang J, Song X. Exploring causal effects of smoking and alcohol related lifestyle factors on self-report tiredness: A Mendelian randomization study. PloS One. 2023 Jun 16;18(6):e0287027. doi:10.1371/journal.pone.0287027
100. Drent M, Jessurun NT, Wijnen PA, Bekers O, Bast A. Drug-induced comorbidities in patients with sarcoidosis. Curr Opin Pulm Med. 2022 Sep 1;28(5):468–77. doi:10.1097/MCP.0000000000000889
101. Holland AE, Wadell K, Spruit MA. How to adapt the pulmonary rehabilitation programme to patients with chronic respiratory disease other than COPD. Eur Respir Rev. 2013 Dec;22(130):577–86. doi:10.1183/09059180.00005613
102. Vanmaris RMM, Rijkers GT. Biological role of the soluble interleukin-2 receptor in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122–9. doi:10.36141/svdld.v34i2.5369
103. Druyan A, Shuv N, Lidar M. Put Down the ACE: Low Clinical Utility for Angiotensin-Converting Enzyme Levels in Sarcoidosis: A Single-Center Retrospective Cohort Study. J Clin Med. 2024 Dec 16;13(24):7657. doi:10.3390/jcm13247657
104. Schwartz JR, Khan A, Mccall WV, Weintraub J, Tiller J. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. J Clin Sleep Med. 2010 Oct 15;6(5):450–7.
105. Stuhec M, Lukić P, Locatelli I. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019 Feb;53(2):121–33. doi:10.1177/1060028018795703
106. Childress AC, Marraffino A, Cutler AJ, Oh C, Brams MN. Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. J Child Adolesc Psychopharmacol. 2023 Mar;33(2):51–8. doi:10.1089/cap.2022.0076
107. Saadh MJ, Saleh AY, Kareem RA, Sharma R, Roopashree R, Chandra Sharma G, et al. Exercise as a therapeutic strategy for insomnia: Current mechanisms and clinical relevance. Sleep Med. 2025 Feb;138:108681. doi:10.1016/j.sleep.2025.108681
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
